Immunome IMNM Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Immunome’s reported figures.
Based on trailing twelve months.
The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunome's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunome's return on equity?
- Immunome (IMNM) reported return on equity of -50.1% in Q1 2026.
- How has Immunome's return on equity changed year-over-year?
- Immunome's return on equity increased by 27.6% year-over-year, from -69.2% to -50.1%.
- What is the long-term trend for Immunome's return on equity?
- Over 4 years (2021 to 2025), Immunome's return on equity has grown at a -1.4% compound annual growth rate (CAGR), from -55.2% to -52.1%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.